NAMSA expands US footprint with Labcorp medical device testing acquisition
The deal brings Labcorp’s U.S. portfolio—including biocompatibility, microbiological, and analytical testing, as well as preclinical research—under NAMSA’s roof
The deal brings Labcorp’s U.S. portfolio—including biocompatibility, microbiological, and analytical testing, as well as preclinical research—under NAMSA’s roof
GlideTech materials are available in several standard base resins and offer customization options for specific applications
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
Subscribe To Our Newsletter & Stay Updated